Although polio no longer causes widespread fear as it once did, the global effort to eradicate the three types of polioviruses has been an ongoing human endeavor for the past few decades. In 2001, Kid Risk, Inc. launched a collaboration with the Centers of Disease Control and Prevention (CDC) with initial support from the CDC-Harvard Joint Initiative in Vaccine Economics (JIVE). Our long-standing collaboration with the Global Polio Eradication Initiative partners created prize-winning analytical modeling tools to help decision makers consider the implications of the various global immunization and risk management choices after eradicating wild polioviruses. Today, our research on polio continues to generate many presentations and peer-reviewed publications.

Increasing population immunity prior to globally-coordinated cessation of bivalent oral poliovirus vaccine (bOPV)

Badizadegan ND, Wassilak SGF, Estívariz CF, Wiesen E, Burns CC, Bolu O, Thompson KM

Pathogens, 2024; 13(9):804, doi:10.3390/pathogens13090804

Evolution of global polio eradication strategies: Targets, vaccines, and supplemental immunization activities (SIAs)

Thompson KM, Badizadegan K

Expert Rev Vaccines, 2024; doi:10.1080/14760584.2024.2361060.

Review of poliovirus transmission and economic modeling to support global polio eradication: 2020–2024

Thompson KM, Badizadegan K

Pathogens, 2024; 13(6):435, doi:10.3390/pathogens13060435.

Contribution of vaccination to improved survival and health: Modelling 50 years of the Expanded Programme on Immunization

Shattock AJ, Johnson HC, Sim SY, Carter A, Lambach P, Hutubessy RCW, Thompson KM, Badizadegan K, Lambert B, Ferrari MJ, Jit M, Fu H, Silal SP, Hounsell RA, White RG, Mosser JF, Gaythorpe KAM, Trotter CL, Lindstrand A, O'Brien KL, Bar-Zeev N

Lancet, 2024; 403(10441):2307-2316, doi:10.1016/S0140-6736(24)00850-X.

Trade-offs of different poliovirus vaccine options for outbreak response in the United States and other countries that only use inactivated poliovirus vaccine (IPV) in routine immunization

Thompson KM, Kalkowsa DA, Kidd SE, Burns CC, Badizadegan K

Vaccine, 2024; 42(4):819-827, doi:10.1016/j.vaccine.2023.12.081

Modeling undetected poliovirus circulation following the 2022 outbreak in the United States

Kalkowska DA, Badizadegan K, Routh JA, Burns CC, Rosenberg ES, Brenner IR, Zucker JR, Langdon-Embry M, Thompson KM

Expert Rev Vaccines, 2024; 23(1):186-195. doi:10.1080/14760584.2023.2299401.

Oral polio vaccine stockpile modeling: Insights from recent experience

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2023; 22(1):813-825. doi:10.1080/14760584.2023.2263096.

Health economic analysis of antiviral drugs in the global polio eradication endgame

Badizadegan K, Kalkowska DA, Thompson KM

Med Decis Making, 2023:272989x231191127. doi:10.1177/0272989x231191127.



Modeling poliovirus transmission and responses in New York State

Thompson KM, Kalkowska DA, Routh JA, Brenner IR, Rosenberg ES, Zucker JR, Langdon-Embry M, Sugerman DE, Burns CC, Badizadegan K

J Infec Dis 2023 Aug 19;jiad355. doi:10.1093/infdis/jiad355. Online ahead of print.

Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences

Kalkowska DA, Wassilak SGF, Wiesen E, Burns CC, Pallansch MA, Badizadegan K, Thompson KM

Risk Anal, 2023, online ahead of print. doi:10.1111/risa.14158.



Worst-case scenarios: Modeling uncontrolled type 2 polio transmission

Kalkowska DA, Wiesen E, Wassalik SGF, Burns CC, Pallansch MA, Badizadegan K, Thompson KM

Risk Anal, 2023, online ahead of print. doi:10.1111/risa.14159.



Pinned Video:   The U.S. Centers for Disease Control & Prevention (CDC) and Kid Risk, Inc.: Polio eradicators use integrated analytical models to make better decisions

Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL

2014 Edelman Award lecture & presentation slides

Polio endgame complexity: Updating expectations for nOPV2

Thompson KM

Lancet Infect Dis, 2023; S1473-3099(23)00133-0. doi:10.1016/S1473-3099(23)00133-0.



Outbreak management strategies for cocirculation of multiple poliovirus types

Kalkowska DA, Badizadegan K, Thompson KM

Vaccine, 2023; doi:10.1016/j.vaccine.2023.04.037.



Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation

Kalkowsa DA, Wassilak SGF, Wiesen E, Estivariz CF, Burns CC, Badizadegan K, Thompson KM

Gates Open Res, 2023; 7:55. doi: 10.12688/gatesopenres.14511.1. eCollection 2023..

Looking back at prospective modeling of outbreak response strategies for managing global type 2 oral poliovirus vaccine (OPV2) cessation

Thompson KM, Kalkowska DA, Badizadegan K

Front Public Health, 2023; 11. doi:10.3389/fpubh.2023.1098419.

Effectiveness of a new vaccine for outbreak response and the increasingly complicated polio endgame

Thompson KM

Lancet Glob Health, 2022; 10(12):e1697-e1698. doi:10.1016/S2214-109X(22)00452-1.

Polio eradication: Addressing the hurdles on the last mile

Thompson KM, Lauring AS, Pollard AJ, Andino R, Bandyopadhyay AS, Berkley S, Bhutta ZA, Routh J, Benn CS

Cell, 2023; 186(1):1-4. doi:10.1016/j.cell.2022.12.021.

Outbreak response strategies with type 2-containing oral poliovirus vaccines

Kalkowsa DA, Wassilak SGF, Pallansch MA, Burns CC, Wiessen ED, Badizadegan K, Thompson KM

Vaccine, 2023; 41 Suppl 1:A142-A152. (Epub date 20221117) doi:10.1016/j.vaccine.2022.10.060.

Health economic analysis of vaccine options for the polio eradication endgame: 2022-2036

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2022. 21(11):1667-1674. doi:10.1080/14760584.2022.2128108.

Polio by the numbers – A global perspective

Badizadegan K, Kalkowska DA, Thompson KM

J Infect Dis, 2022. 226(8):1309–1318. doi:10.1093/infdis/jiac130.



Modeling undetected live type 1 wild poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan

Kalkowsa DA, Badizadegan K, Thompson KM

Risk Anal, 2023. 43(4):677-685. doi: 10.1111/risa.13982. Epub 2022 Jun 23.

Modeling scenarios for ending poliovirus transmission in Pakistan and Afghanistan

Kalkowsa DA, Badizadegan K, Thompson KM

Risk Anal, 2023. 43(4):660-676. doi: 10.1111/risa.13983. Epub 2022 Jun 23.

Polio health economics: Assessing the benefits and costs of polio, non-polio, and integrated activities of the Global Polio Eradication Initiative

Thompson K, Kalkowska D, Badizadegan K

Gates Open Research, 2022; 6(5). doi:10.12688/gatesopenres.13524.1.

Health economic analyses of secondary vaccine effects: A systematic review and policy insights

Thompson KM, Badizadegan K

Expert Rev Vaccines, 2022:1-16. doi:10.1080/14760584.2022.2017287.

Polio eradication: What kind of world do we want?

Thompson KM

Lancel Infect Dis, 2022; 22(2):161-163. doi:10.1016/S1473-3099(21)00458-8.



Modeling poliovirus surveillance and immunization campaign quality monitoring costs for Pakistan and Afghanistan for 2019-2023

Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM

Open Forum Infect Dis, 2021. doi:10.1093/ofid/ofab264.

Serotype 2 oral poliovirus vaccine (OPV2) choices and the consequences of delaying outbreak response

Kalkowska DA, Pallansch MA, Wassilak SGF, Cochi SL, Thompson KM

Vaccine, 2023; 41 Suppl 1:A136-A141. (Epub date 20210514) doi:10.1016/j.vaccine.2021.04.061.

The impact of disruptions caused by the COVID-19 pandemic on global polio eradication

Kalkowska DA, Voorman A, Pallansch MA, Wassilak SGF, Cochi SL, Badizadegan K, Thompson KM

Vaccine, 2023; 41 Suppl 1:A12-A18. (Epub date 20210427) doi:10.1016/j.vaccine.2021.04.026.

Updated characterization of poliovirus transmission in Pakistan and Afghanistan and the impacts of different outbreak response vaccine options

Kalkowska DA, Pallansch MA, Cochi SL, Thompson KM

J Infect Dis, 2021. doi:10.1093/infdis/jiab160.

Hypothetical emergence of poliovirus in 2020: Part 1. Consequences of policy decisions to respond using nonpharmaceutical interventions

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891888.

Hypothetical emergence of poliovirus in 2020: Part 2. Exploration of the potential role of vaccines in control and eradication

Thompson KM, Kalkowska DA, Badizadegan K

Expert Rev Vaccines, 2021. doi:10.1080/14760584.2021.1891889.

Health and economic outcomes associated with polio vaccine policy options: 2019–2029

Kalkowska DA, Thompson KM

Risk Anal, 2021; 41(2):364-375. doi:10.1111/risa.13664.

Modeling and managing poliovirus risks: We are where we are…

Thompson KM

Risk Anal, 2021; 41(2):223-228. doi:10.1111/risa.13668.

An updated economic analysis of the global polio eradication initiative

Thompson KM, Kalkowska DA

Risk Anal, 2021; 41(2):393-406. doi:10.1111/risa.13665.

Poliovirus vaccine options: Another step forward

Thompson KM

The Lancet, 2021. doi:10.1016/S0140-6736(20)32629-5.

Updated characterization of outbreak response strategies for 2019-2029: Impacts of using a novel type 2 oral poliovirus vaccine strain

Kalkowska DA, Pallansch MA, Wilkinson A, Bandyopadhyay AS, Konopka-Anstadt JL, Burns CC, Oberste MS, Wassilak SGF, Badizadegan K, Thompson KM

Risk Anal, 2021. doi:10.1111/risa.13622.

No role for reintroducing OPV into the United States with respect to controlling COVID-19 [Response to the letter to the Editor by Chumakov et al.]

Thompson KM, Kalkowska DA, Badizadegan K

Risk Anal, 2021; 41(2):389-392. doi:10.1111/risa.13671.

A health economic analysis for oral poliovirus vaccine to prevent COVID-19 in the United States

Thompson KM, Kalkowska DA, Badizadegan K

Risk Anal, 2021; 41(2):376-386. doi:10.1111/risa.13614.

Expected implications of globally coordinated cessation of serotype 3 oral poliovirus vaccine (OPV) before serotype 1 OPV

Kalkowska DA, Thompson KM

Risk Anal, 2021; 41(2):312-319. doi:10.1111/risa.13590.

Potential future use, costs, and value of poliovirus vaccines

Thompson KM, Kalkowska DA

Risk Anal, 2021; 41(2):349-363. doi:10.1111/risa.13557.

Updated characterization of post-OPV cessation risks: Lessons from 2019 serotype 2 outbreaks and implications for the probability of OPV restart

Kalkowska DA, Pallansch MA, Cochi SL, Kovacs SD, Wassilak SGF, Thompson KM

Risk Anal, 2021; 41(2):320-328. doi:10.1111/risa.13555.

Review of poliovirus modeling performed from 2000 to 2019 to support global polio eradication

Thompson KM, Kalkowska DA

Expert Rev Vaccines, 2020:1-25. doi:10.1080/14760584.2020.1791093.

Reflections on modeling poliovirus transmission and the polio eradication endgame

Thompson KM, Kalkowska DA

Risk Anal, 2021; 41(2):229-247. doi:10.1111/risa.13484.

Modeling undetected live poliovirus circulation after apparent interruption of transmission: Borno and Yobe in northeast Nigeria

Kalkowska DA, Thompson KM

Risk Anal, 2021; 41(2):303-311. doi:10.1111/risa.13486.

Modeling poliovirus transmission in Borno and Yobe, northeast Nigeria

Kalkowska DA, Franka R, Higgins J, Kovacs SD, Forbi JC, Wassilak SGF, Pallansch MA, Thompson KM

Risk Anal, 2021; 41(2):289-302. doi:10.1111/risa.13485.

Insights from modeling preventive supplemental immunization activities as a strategy to eliminate wild poliovirus transmission in Pakistan and Afghanistan

Kalkowska DA, Thompson KM

Risk Anal, 2020. doi:10.1111/risa.13471.

The potential role of using vaccine patches to induce immunity: platform and pathways to innovation and commercialization

Badizadegan K, Goodson JL, Rota PA, Thompson KM

Expert Rev Vaccines, 2020; 19(2):175-194. doi:10.1080/14760584.2020.1732215.

Global transmission of live polioviruses: Updated dynamic modeling of the polio endgame

Kalkowska DA, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM

Risk Anal, 2020. doi: 10.1111/risa.13447. Epub 2020 Jan 20.

Updated modelling of the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus (iVDPV) excreters

Kalkowska DA, Pallansch MA, Thompson KM

Epidemiol Infect, 2019; published online 24 October 2019, e295.

Logistical challenges and assumptions for modeling the failure of global cessation of oral Poliovirus vaccine (OPV)

Thompson KM, Kalkowska DA

Expert Rev Vaccines, 2019 Jul;18(7):725-736. doi: 10.1080/14760584.2019.1635463. Epub 2019 Jul 2.

Polio endgame options: Will we have the vaccines needed?

Thompson KM

Lancet, 2019 Jul 13;394(10193):99-100. doi: 10.1016/S0140-6736(19)31294-2. Epub 2019 Jun 4.

Characterizing the costs of the global polio laboratory network: A survey-based analysis

Duintjer Tebbens RJ, Diop OM, Pallansch MA, Oberste MS, Thompson KM

BMJ Open, 2019 Jan 21;9(1):e023290. doi: 10.1136/bmjopen-2018-023290.

Global certification of wild poliovirus eradication: Insights from modelling hard-to-reach subpopulations and confidence about the absence of transmission

Duintjer Tebbens RJ, Kalkowska DA, Thompson KM

BMJ Open, 2019 Jan 15;9(1):e023938. doi: 10.1136/bmjopen-2018-023938.


Evaluation of proactive and reactive strategies for polio eradication activities in Pakistan and Afghanistan

Duintjer Tebbens RJ, Thompson KM

Risk Anal, 2019 Feb;39(2):389-401. doi: 10.1111/risa.13194. Epub 2018 Sep 21.

Modeling undetected live poliovirus circulation after apparent interruption of transmission: Pakistan and Afghanistan

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Thompson KM

Risk Anal, 2019 Feb;39(2):402-413. doi: 10.1111/risa.13214. Epub 2018 Oct 8.

Environmental surveillance system characteristics and impacts on confidence about no undetected serotype 1 wild poliovirus circulation

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM

Risk Anal, 2019 Feb;39(2):414-425. doi: 10.1111/risa.13193. Epub 2018 Sep 21.

Polio endgame risks and the possibility of restarting the use of oral poliovirus vaccine

Duintjer Tebbens RJ, Thompson KM

Expert Rev Vaccines, 2018 Aug;17(8):739-751. doi: 10.1080/14760584.2018.1506333. Epub 2018 Aug 9.

Another look at silent circulation of poliovirus in small populations

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM

Infectious Disease Modeling, 2018; 3:107-117. doi:10.1016/j.idm.2018.06.001.

Poliovirus containment risks and their management

Duintjer Tebbens RJ, Kalkowska DA, Thompson KM

Future Virology, 2018; 13(9):617-628, doi: 10.2217/fvl-2018-0079.

Using integrated modeling to support the global eradication of vaccine-preventable diseases

Thompson KM, Duintjer Tebbens RJ

System Dynamics Review, 2018;34(1-2):78-120. doi:10.1002/sdr.1589.

Planning for globally coordinated cessation of bivalent oral poliovirus vaccine: risks of non-synchronous cessation and unauthorized oral poliovirus vaccine use

Duintjer Tebbens RJ, Hampton LM, Thompson KM

BMC Infect Dis, 2018; 18:165. doi:10.1186/s12879-018-3074-0.

Modeling poliovirus transmission in Pakistan and Afghanistan to inform vaccination strategies in undervaccinated subpopulations

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Ehrhardt DT, Farag NH, Hadler SC, Hampton LM, Martinez M, Wassilak SGF, Thompson KM

Risk Anal, 2018 Aug;38(8):1701-1717. doi: 10.1111/risa.12962. Epub 2018 Jan 3.

Lessons from the polio endgame: overcoming the failure to vaccinate and the role of subpopulations in maintaining transmission

Thompson KM, Duintjer Tebbens RJ

J Infect Dis, 2017 Jul 1;216(suppl_1):S176-S182. doi: 10.1093/infdis/jix108.

Lessons from globally coordinated cessation of serotype 2 oral poliovirus vaccine for the remaining serotypes

Thompson KM, Duintjer Tebbens RJ

J Infect Dis, 2017 Jul 1;216(suppl_1):S168-S175. doi: 10.1093/infdis/jix128.

Insights from a systematic search for information on designs, costs, and effectiveness of poliovirus environmental surveillance systems

Duintjer Tebbens RJ, Zimmermann M, Pallansch MA, Thompson KM

Food Environ Virol, 2017 Dec;9(4):361-382. doi: 10.1007/s12560-017-9314-4. Epub 2017 Jul 7.

Modeling the costs and benefits of temporary recommendations for poliovirus exporting countries to vaccinate international travelers

Duintjer Tebbens RJ, Thompson KM

Vaccine, 2017 Jul 5;35(31):3823-3833. doi: 10.1016/j.vaccine.2017.05.090. Epub 2017 Jun 9.

Poliovirus vaccination during the endgame: insights from integrated modeling

Duintjer Tebbens RJ, Thompson KM

Expert Rev Vaccines, 2017 Jun;16(6):577-586. doi:10.1080/14760584.2017.1322514. Epub 2017 May 9.

Costs and benefits of including inactivated in addition to oral poliovirus vaccine in outbreak response after cessation of oral poliovirus vaccine use

Duintjer Tebbens RJ, Thompson KM

Medical Decision Making Policy & Practice, 2017; 2(1):1-13, doi:10.1177/2381468317697002.

How should we prepare for an outbreak of reintroduced live polioviruses?

Thompson KM, Duintjer Tebbens RJ

Future Virology, 2017; 12(2):41-44, doi:10.2217/fvl-2016-0131.



The potential benefits of a new poliovirus vaccine for long-term poliovirus risk management

Duintjer Tebbens RJ, Thompson KM

Future Microbiology, 2016; 11(12):1549-1561, doi:10.2217/fmb-2016-0126

Comprehensive screening for immunodeficiency-associated vaccine-derived poliovirus: an essential oral poliovirus vaccine cessation risk management strategy

Duintjer Tebbens RJ, Thompson KM

Epidemiology and Infection, 2017; 145(2):217-226, doi: 10.1017/S0950268816002302.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of inadvertent trivalent oral poliovirus vaccine use

Duintjer Tebbens RJ, Hampton LM, Thompson KM

BMC Infect Dis, 2016; 16:237. doi:10.1186/s12879-016-1537-8.

Uncertainty and Sensitivity analysis of cost assumptions for global long-term poliovirus risk management

Duintjer Tebbens RJ, Thompson KM

J Vaccines Vaccin, 2016; 7(5):1000339. doi:10.4172/2157-7560.1000339.

Implementation of coordinated global serotype 2 oral poliovirus vaccine cessation: risks of potential non-synchronous cessation

Duintjer Tebbens RJ, Hampton LM, Thompson KM

BMC Infect Dis, 2016; 16:231. doi:10.1186/s12879-016-1536-9.

Maintenance and intensification of bivalent oral poliovirus vaccine use prior to its coordinated global cessation

Tebbens RJD, Hampton LM, Wassilak SGF, Pallansch MA, Cochi SL, Thompson KM

J Vaccines Vaccin, 2016; 7(5). doi:10.4172/2157-7560.1000340.

Characterization of outbreak response strategies and potential vaccine stockpile needs for the polio endgame

Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM

BMC Infect Dis, 2016; 16:137. doi:10.1186/s12879-016-1465-7.

Managing the risk of circulating vaccine-derived poliovirus during the endgame: oral poliovirus vaccine needs

Duintjer Tebbens RJ, Thompson KM

BMC Infect Dis, 2015; 15:390. doi:10.1186/s12879-015-1114-6.

Modeling the prevalence of immunodeficiency-associated long-term vaccine-derived poliovirus excretors and the potential benefits of antiviral drugs

Duintjer Tebbens RJ, Pallansch MA, Thompson KM

BMC Infect Dis, 2015; 15:379. doi:10.1186/s12879-015-1115-5.

An economic analysis of poliovirus risk management policy options for 2013-2052

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM.

BMC Infect Dis, 2015; 15:389. doi:10.1186/s12879-015-1112-8.

Health and economic consequences of different options for timing the coordinated global cessation of the three oral poliovirus vaccine serotypes

Thompson KM, Duintjer Tebbens RJ

BMC Infect Dis, 2015; 15:374. doi:10.1186/s12879-015-1113-7.

The differential impact of oral poliovirus vaccine formulation choices on serotype-specific population immunity to poliovirus transmission

Thompson KM, Duintjer Tebbens RJ

BMC Infect Dis, 2015; 15:376. doi:10.1186/s12879-015-1116-4.



Good news for billions of children who will receive IPV

Thompson KM

Lancet Infect Dis, 2015; 15(10):1120-1122. doi:10.1016/S1473-3099(15)00099-7.

Combinations of quality and frequency of immunization activities to stop and prevent poliovirus transmission in the high-risk area of northwest Nigeria

Duintjer Tebbens RJ, Pallansch MA, Wassilak SG, Cochi SL, Thompson KM

PLoS One, 2015; 10(6):e0130123. doi:10.1371/journal.pone.0130123.

Characterization of heterogeneity in childhood immunization coverage in central Florida using immunization registry data

Thompson KM, Logan GE; Florida SHOTS™ Research Team

Risk Anal, 2016;36(7):1418-26. doi: 10.1111/risa.12424. Epub 2015 May 29.

Polio eradicators use integrated analytical models to make better decisions

Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Wassilak SGF, Cochi SL

Interfaces, 2015; 45(1):5-25.

        

Managing population immunity to reduce or eliminate the risks of circulation following the importation of polioviruses

Thompson KM, Kalkowska DA, Duintjer Tebbens RJ

Vaccine, 2015; 33(13):1568-77. doi:10.1016/j.vaccine.2015.02.013.

Modeling undetected live poliovirus circulation after apparent interruption of transmission: implications for surveillance and vaccination

Kalkowska DA, Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM

BMC Infect Dis, 2015; 15:66. doi:10.1186/s12879-015-0791-5.

Modeling options to manage population immunity and the impact of asymptomatic wild poliovirus transmission in Israel

Kalkowska DA, Duintjer Tebbens RJ, Grotto I, Shulman LM, Anis E, Wassilak SG, Pallansch MA, Thompson KM

J Infect Dis, 2015; 211(11):1800-12. doi:10.1093/infdis/jiu674.

Modeling the dynamics of oral poliovirus vaccine cessation

Thompson KM, Duintjer Tebbens RJ

J Infect Dis, 2014; 210 Suppl 1:S475-84. doi:10.1093/infdis/jit845.


Individual-based modeling of potential poliovirus transmission in connected religious communities in North America with low uptake of vaccination

Kisjes KH, Duintjer Tebbens RJ, Wallace GS, Pallansch MA, Cochi SL, Wassilak SG, Thompson KM

J Infect Dis, 2014; 210 Suppl 1:S424-33. doi:10.1093/infdis/jit843.

Modeling the potential role of inactivated poliovirus vaccine to manage the risks of oral poliovirus vaccine cessation

Duintjer Tebbens RJ, Thompson KM

J Infect Dis, 2014; 210 Suppl 1:S485-97. doi:10.1093/infdis/jit838.

Modeling strategies to increase population immunity and prevent poliovirus transmission in 2 high-risk areas in northern India

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM

J Infect Dis, 2014; 210 Suppl 1:S398-411. doi:10.1093/infdis/jit844.

Modeling strategies to increase population immunity and prevent poliovirus transmission in the high-risk area of northwest Nigeria

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM

J Infect Dis, 2014; 210 Suppl 1:S412-23. doi:10.1093/infdis/jit834.

Polio endgame management: focusing on performance with or without inactivated poliovirus vaccine

Thompson KM

Lancet, 2014; 384(9953):1480-2. doi:10.1016/S0140-6736(14)60983-1.

The potential impact of expanding target age groups for polio immunization campaigns

Duintjer Tebbens RJ, Kalkowska DA, Wassilak SG, Pallansch MA, Cochi SL, Thompson KM

BMC Infect Dis, 2014; 14:45. doi:10.1186/1471-2334-14-45.

National choices related to inactivated poliovirus vaccine, innovation and the endgame of global polio eradication

Thompson KM, Duintjer Tebbens RJ

Expert Rev Vaccines, 2014; 13(2):221-34. doi:10.1586/14760584.2014.864563.

Preeradication vaccine policy options for poliovirus infection and disease control

Thompson KM, Pallansch MA, Duintjer Tebbens RJ, Wassilak SG, Kim JH, Cochi SL

Risk Anal, 2013; 33(4):516-43. doi:10.1111/risa.12019.

Oral poliovirus vaccine evolution and insights relevant to modeling the risks of circulating vaccine-derived polioviruses (cVDPVs)

Duintjer Tebbens RJ, Pallansch MA, Kim JH, Burns CC, Kew OM, Oberste MS, Diop OM, Wassilak SG, Cochi SL, Thompson KM

Risk Anal, 2013; 33(4):680-702. doi:10.1111/risa.12022.

Characterizing poliovirus transmission and evolution: insights from modeling experiences with wild and vaccine-related polioviruses

Duintjer Tebbens RJ, Pallansch MA, Kalkowska DA, Wassilak SG, Cochi SL, Thompson KM

Risk Anal, 2013; 33(4):703-49. doi:10.1111/risa.12044.

Modeling population immunity to support efforts to end the transmission of live polioviruses

Thompson KM, Pallansch MA, Tebbens RJ, Wassilak SG, Cochi SL

Risk Anal, 2013; 33(4):647-63. doi:10.1111/j.1539-6924.2012.01891.x.

Expert review on poliovirus immunity and transmission

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM

Risk Anal, 2013; 33(4):544-605. doi:10.1111/j.1539-6924.2012.01864.x.

Review and assessment of poliovirus immunity and transmission: synthesis of knowledge gaps and identification of research needs

Duintjer Tebbens RJ, Pallansch MA, Chumakov KM, Halsey NA, Hovi T, Minor PD, Modlin JF, Patriarca PA, Sutter RW, Wright PF, Wassilak SG, Cochi SL, Kim JH, Thompson KM

Risk Anal, 2013; 33(4):606-46. doi:10.1111/risa.12031.

Global ICU: valuing prevention as the new paradigm in global health

Thompson KM

ICU Management 2012; 12(4):9-11.

Trends in the risk of U.S. polio outbreaks and poliovirus vaccine availability for response

Thompson KM, Wallace GS, Duintjer Tebbens RJ, Smith PJ, Barskey AE, Pallansch MA, Gallagher KM, Alexander JP, Armstrong GL, Cochi SL, Wassilak SG

Public Health Rep, 2012; 127(1):23-37. doi:10.1177/003335491212700104.

Modeling poliovirus risks and the legacy of polio eradication

Thompson KM

Risk Anal, 2013; 33(4):505-15. doi:10.1111/risa.12030.

Current polio global eradication and control policy options: perspectives from modeling and prerequisites for oral poliovirus vaccine cessation

Thompson KM, Duintjer Tebbens RJ

Expert Rev Vaccines, 2012; 11(4):449-59. doi:10.1586/erv.11.195.

The role of risk analysis in polio eradication: modeling possibilities, probabilities and outcomes to inform choices

Thompson KM

Expert Rev Vaccines, 2012; 11(1):5-7. doi:10.1586/erv.11.163.

The probability of undetected wild poliovirus circulation after apparent global interruption of transmission

Kalkowska DA, Duintjer Tebbens RJ, Thompson KM

Am J Epidemiol, 2012; 175(9):936-49. doi:10.1093/aje/kwr399.

Group report: developing an eradication investment case

Thompson KM, Rabinovich R, Conteh L, Emerson CI, Hall BF, Singer PA, Vijayaraghavan M, Walker DG

In Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press: 2011; 133-148.

Economic evaluation of the benefits and costs of disease elimination and eradication initiative

Thompson KM, Duintjer Tebbens RJ

In Disease Eradication in the 21st Century: Implications for Global Health. Cochi SL and Dowdle WR (eds). Cambridge, MA: MIT Press: 2011; 115-130.

Economic analysis of the global polio eradication initiative

Duintjer Tebbens RJ, Pallansch MA, Cochi SL, Wassilak SG, Linkins J, Sutter RW, Aylward RB, Thompson KM

Vaccine, 2010; 29(2):334-43. doi:10.1016/j.vaccine.2010.10.026.

        

Development of an individual-based model for polioviruses: implications of the selection of network type and outcome metrics

Rahmandad H, Hu K, Duintjer Tebbens RJ, Thompson KM

Epidemiol Infect, 2011; 139(6):836-48. doi:10.1017/S0950268810001676.

Optimal vaccine stockpile design for an eradicated disease: application to polio

Tebbens RJ, Pallansch MA, Alexander JP, Thompson KM

Vaccine, 2010; 28(26):4312-27. doi:10.1016/j.vaccine.2010.04.001.

Priority shifting and the dynamics of managing eradicable infectious diseases

Duintjer Tebbens RJ, Thompson KM

Manag Sci, 2009; 55(4):650-63. doi:10.1287/mnsc.1080.0965.

Using system dynamics to develop policies that matter: global management of poliomyelitis and beyond

Duintjer Tebbens RJ, Thompson KM

Syst Dynam Rev, 2008; 24:433-49. doi:10.1002/sdr.

The risks, costs, and benefits of possible future global policies for managing polioviruses

Thompson KM, Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary HE, Jr., Alexander J, Jafari H, Cochi SL

Am J Public Health, 2008; 98(7):1322-30. doi:10.2105/AJPH.2007.122192.

The case for cooperation in managing and maintaining the end of poliomyelitis: stockpile needs and coordinated OPV cessation

Thompson KM, Duintjer Tebbens RJ

Medscape J Med, 2008; 10(8):190.

Uncertainty and sensitivity analyses of a decision analytic model for posteradication polio risk management

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Bruce Aylward R, Watkins M, Gary H, Alexander J, Jafari H, Cochi SL, Thompson KM

Risk Anal, 2008; 28(4):855-76. doi:10.1111/j.1539-6924.2008.01078.x.

Eradication versus control for poliomyelitis: an economic analysis

Thompson KM, Duintjer Tebbens RJ

Lancet, 2007; 369(9570):1363-1371. doi:10.1016/S0140-6736(07)60532-7.

Winner of 2008 Jay Forrester Award for best contribution to the field of System Dynamics during the preceding 5 years.

        

Eradicating polio: The dollars and sense

Thompson KM

MedGenMed, 2007; 9(4):11.

Development and consideration of global policies for managing the future risks of poliovirus outbreaks: insights and lessons learned through modeling

Thompson KM, Duintjer Tebbens RJ, Pallansch MA, Kew OM, Sutter RW, Aylward RB, Watkins M, Gary H, Alexander JP, Venczel L, Johnson D, Caceres VM, Sangrujee N, Jafari H, Cochi SL

Risk Anal, 2006; 26(6):1571-80. doi:10.1111/j.1539-6924.2006.00841.x.

Evaluation of response scenarios to potential polio outbreaks using mathematical models

Thompson KM, Duintjer Tebbens RJ, Pallansch MA

Risk Anal, 2006; 26(6):1541-56. doi:10.1111/j.1539-6924.2006.00843.x.

The costs of future polio risk management policies

Tebbens RJ, Sangrujee N, Thompson KM

Risk Anal, 2006; 26(6):1507-31. doi:10.1111/j.1539-6924.2006.00842.x.

Global surveillance and the value of information: the case of the global polio laboratory network

de Gourville E, Duintjer Tebbens RJ, Sangrujee N, Pallansch MA, Thompson KM

Risk Anal, 2006; 26(6):1557-69. doi:10.1111/j.1539-6924.2006.00845.x.

Retrospective cost-effectiveness analyses for polio vaccination in the United States

Thompson KM, Duintjer Tebbens RJ

Risk Anal, 2006; 26(6):1423-40. doi:10.1111/j.1539-6924.2006.00831.x.

Poliomyelitis and the role of risk analysis in global infectious disease policy and management

Thompson KM

Risk Anal, 2006; 26(6):1419-21. doi:10.1111/j.1539-6924.2006.00853.x.

Risks of paralytic disease due to wild or vaccine-derived poliovirus after eradication

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Jafari H, Cochi SL, Sutter RW, Aylward RB, Thompson KM

Risk Anal, 2006; 26(6):1471-505. doi:10.1111/j.1539-6924.2006.00827.x.

Risk management in a polio-free world

Bruce Aylward R, Sutter RW, Cochi SL, Thompson KM, Jafari H, Heymann D

Risk Anal, 2006; 26(6):1441-8. doi:10.1111/j.1539-6924.2006.00840.x.

A dynamic model of poliomyelitis outbreaks: learning from the past to help inform the future

Duintjer Tebbens RJ, Pallansch MA, Kew OM, Caceres VM, Sutter RW, Thompson KM

Am J Epidemiol, 2005; 162(4):358-72. doi:10.1093/aje/kwi206.

Policy decision options during the first 5 years following certification of polio eradication

Sangrujee N, Duintjer Tebbens RJ, Caceres VM, Thompson KM

Medscape Gen Med, 2003; 5(4):35.

©2024 Kid Risk, Inc. All rights reserved.